CAPTRUST Financial Advisors
SCNI

CAPTRUST Financial Advisors’s Scinai Immunotherapeutics SCNI Stock Holding History

CAPTRUST Financial Advisors’s Portfolio SCNI Stock Details SCNI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.04K Buy
+1,204
New +$5.92K ﹤0.01% 3260
2022
Q3 		– Sell
-1
Closed -$1K – 3688
2022
Q2 		$1K Hold
1
– – ﹤0.01% 4735
2022
Q1 		$2K Hold
1
– – ﹤0.01% 4536
2021
Q4 		$2K Hold
1
– – ﹤0.01% 4441
2021
Q3 		$2K Hold
1
– – ﹤0.01% 4296
2021
Q2 		$3K Hold
1
– – ﹤0.01% 4055
2021
Q1 		$5K Hold
1
– – ﹤0.01% 3745
2020
Q4 		$3K Hold
1
– – ﹤0.01% 3030
2020
Q3 		$47K Buy
+1
New +$38.4K ﹤0.01% 1657

Other funds holding SCNI

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

CAPTRUST Financial Advisors's SCNI Position: Q2 2026 in Review

CAPTRUST Financial Advisors opened a new position in Scinai Immunotherapeutics (SCNI) in Q2 2026: 1,204 shares worth $3.04K. The stake represents ﹤0.01% of the portfolio and ranks #3260 among its holdings. This is a return to the name: CAPTRUST Financial Advisors previously reported a position in SCNI as recently as Q2 2022.

CAPTRUST Financial Advisors first reported a position in SCNI in Q3 2020 and has held it in 9 quarters since. The position peaked at $47K in Q3 2020. 11 funds tracked by Wall St. Rank hold SCNI as of Q2 2026.

  • CAPTRUST Financial Advisors held 1,204 shares of Scinai Immunotherapeutics worth $3.04K as of Q2 2026.
  • Scinai Immunotherapeutics was a new CAPTRUST Financial Advisors position in Q2 2026.
  • Scinai Immunotherapeutics made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q2 2026, its #3260 holding.
  • CAPTRUST Financial Advisors first reported a position in Scinai Immunotherapeutics in Q3 2020 and has held it in 9 quarters since.
  • CAPTRUST Financial Advisors's Scinai Immunotherapeutics position peaked at $47K in Q3 2020.
  • 11 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q2 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.